Takeda Pharms Usa patent expiration

1. Actoplus Met patent expiration

ACTOPLUS MET's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6166043 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(8 years ago)

US6172090 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(8 years ago)

US5965584 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(8 years ago)

US6166042 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(8 years ago)

US9101660 TAKEDA PHARMS USA Solid preparation
Jan, 2027

(2 years from now)

US9320714 TAKEDA PHARMS USA Tablet
Feb, 2029

(4 years from now)




Drug Exclusivity Drug Exclusivity Expiration
M(M-116) May 17, 2015

Drugs and Companies using METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE ingredient

Market Authorisation Date: 29 August, 2005

Treatment: Adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes who are already treated with a pioglitazone and metformin; An adjunct to diet and exercise to improve glycemic...

Dosage: TABLET

More Information on Dosage

ACTOPLUS MET family patents

Family Patents

2. Actoplus Met Xr patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5965584 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(8 years ago)

US6166043 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(8 years ago)

US6172090 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(8 years ago)

US6166042 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(8 years ago)

US7919116 TAKEDA PHARMS USA Controlled release metformin formulations
Mar, 2018

(6 years ago)

US6099859 TAKEDA PHARMS USA Controlled release oral tablet having a unitary core
Mar, 2018

(6 years ago)

US8475841 TAKEDA PHARMS USA Controlled release metformin formulations
Mar, 2018

(6 years ago)

US6495162 TAKEDA PHARMS USA Controlled release oral tablet having a unitary core
Mar, 2018

(6 years ago)

US6866866 TAKEDA PHARMS USA Controlled release metformin compositions
Mar, 2021

(3 years ago)

US6790459 TAKEDA PHARMS USA Methods for treating diabetes via administration of controlled release metformin
Mar, 2021

(3 years ago)

US8470368 TAKEDA PHARMS USA Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
Sep, 2023

(9 months ago)

US8668931 TAKEDA PHARMS USA Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
Sep, 2023

(9 months ago)

US9060941 TAKEDA PHARMS USA Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
Sep, 2023

(9 months ago)

US7785627 TAKEDA PHARMS USA Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
Jul, 2026

(2 years from now)

US7959946 TAKEDA PHARMS USA Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
Jul, 2026

(2 years from now)




Drugs and Companies using METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE ingredient

Market Authorisation Date: 12 May, 2009

Treatment: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are already treated with pioglitazone and metformin or who have inadequate glycemic control on piog...

Dosage: TABLET, EXTENDED RELEASE

How can I launch a generic of ACTOPLUS MET XR before it's drug patent expiration?
More Information on Dosage

ACTOPLUS MET XR family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Actos patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6172090 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(8 years ago)

US6329404 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(8 years ago)

US6271243 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(8 years ago)

US6150383 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(8 years ago)

US6166043 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(8 years ago)

US5965584 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(8 years ago)

US6150384 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(8 years ago)

US6211205 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(8 years ago)

US6166042 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(8 years ago)

US6303640 TAKEDA PHARMS USA Pharmaceutical composition
Aug, 2016

(7 years ago)




Drugs and Companies using PIOGLITAZONE HYDROCHLORIDE ingredient

Market Authorisation Date: 15 July, 1999

Treatment: A method for reducing side effects of active components administered to a diabetic patient by administering an insulin sensitivity enhancer (including pioglitazone) in combination with a biguanide as ...

Dosage: TABLET

How can I launch a generic of ACTOS before it's drug patent expiration?
More Information on Dosage

ACTOS family patents

Family Patents

4. Adderall Xr 10 patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE42096 TAKEDA PHARMS USA Oral pulsed dose drug delivery system
Oct, 2018

(5 years ago)

US6605300 TAKEDA PHARMS USA Oral pulsed dose drug delivery system
Oct, 2018

(5 years ago)

USRE41148 TAKEDA PHARMS USA Oral pulsed dose drug delivery system
Oct, 2018

(5 years ago)

US6322819 TAKEDA PHARMS USA Oral pulsed dose drug delivery system
Oct, 2018

(5 years ago)

US6605300

(Pediatric)

TAKEDA PHARMS USA Oral pulsed dose drug delivery system
Apr, 2019

(5 years ago)

USRE42096

(Pediatric)

TAKEDA PHARMS USA Oral pulsed dose drug delivery system
Apr, 2019

(5 years ago)

USRE41148

(Pediatric)

TAKEDA PHARMS USA Oral pulsed dose drug delivery system
Apr, 2019

(5 years ago)

US6322819

(Pediatric)

TAKEDA PHARMS USA Oral pulsed dose drug delivery system
Apr, 2019

(5 years ago)




How can I launch a generic of ADDERALL XR 10 before it's drug patent expiration?
More Information on Dosage

ADDERALL XR 10 family patents

Family Patents

5. Adderall Xr 15 patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE42096 TAKEDA PHARMS USA Oral pulsed dose drug delivery system
Oct, 2018

(5 years ago)

US6605300 TAKEDA PHARMS USA Oral pulsed dose drug delivery system
Oct, 2018

(5 years ago)

USRE41148 TAKEDA PHARMS USA Oral pulsed dose drug delivery system
Oct, 2018

(5 years ago)

US6322819 TAKEDA PHARMS USA Oral pulsed dose drug delivery system
Oct, 2018

(5 years ago)

USRE41148

(Pediatric)

TAKEDA PHARMS USA Oral pulsed dose drug delivery system
Apr, 2019

(5 years ago)

US6605300

(Pediatric)

TAKEDA PHARMS USA Oral pulsed dose drug delivery system
Apr, 2019

(5 years ago)

US6322819

(Pediatric)

TAKEDA PHARMS USA Oral pulsed dose drug delivery system
Apr, 2019

(5 years ago)

USRE42096

(Pediatric)

TAKEDA PHARMS USA Oral pulsed dose drug delivery system
Apr, 2019

(5 years ago)




How can I launch a generic of ADDERALL XR 15 before it's drug patent expiration?
More Information on Dosage

ADDERALL XR 15 family patents

Family Patents

6. Adderall Xr 20 patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6605300 TAKEDA PHARMS USA Oral pulsed dose drug delivery system
Oct, 2018

(5 years ago)

US6322819 TAKEDA PHARMS USA Oral pulsed dose drug delivery system
Oct, 2018

(5 years ago)

USRE42096 TAKEDA PHARMS USA Oral pulsed dose drug delivery system
Oct, 2018

(5 years ago)

USRE41148 TAKEDA PHARMS USA Oral pulsed dose drug delivery system
Oct, 2018

(5 years ago)

USRE42096

(Pediatric)

TAKEDA PHARMS USA Oral pulsed dose drug delivery system
Apr, 2019

(5 years ago)

USRE41148

(Pediatric)

TAKEDA PHARMS USA Oral pulsed dose drug delivery system
Apr, 2019

(5 years ago)

US6605300

(Pediatric)

TAKEDA PHARMS USA Oral pulsed dose drug delivery system
Apr, 2019

(5 years ago)

US6322819

(Pediatric)

TAKEDA PHARMS USA Oral pulsed dose drug delivery system
Apr, 2019

(5 years ago)




How can I launch a generic of ADDERALL XR 20 before it's drug patent expiration?
More Information on Dosage

ADDERALL XR 20 family patents

Family Patents

7. Adderall Xr 25 patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE42096 TAKEDA PHARMS USA Oral pulsed dose drug delivery system
Oct, 2018

(5 years ago)

US6322819 TAKEDA PHARMS USA Oral pulsed dose drug delivery system
Oct, 2018

(5 years ago)

US6605300 TAKEDA PHARMS USA Oral pulsed dose drug delivery system
Oct, 2018

(5 years ago)

USRE41148 TAKEDA PHARMS USA Oral pulsed dose drug delivery system
Oct, 2018

(5 years ago)

US6322819

(Pediatric)

TAKEDA PHARMS USA Oral pulsed dose drug delivery system
Apr, 2019

(5 years ago)

USRE42096

(Pediatric)

TAKEDA PHARMS USA Oral pulsed dose drug delivery system
Apr, 2019

(5 years ago)

USRE41148

(Pediatric)

TAKEDA PHARMS USA Oral pulsed dose drug delivery system
Apr, 2019

(5 years ago)

US6605300

(Pediatric)

TAKEDA PHARMS USA Oral pulsed dose drug delivery system
Apr, 2019

(5 years ago)




How can I launch a generic of ADDERALL XR 25 before it's drug patent expiration?
More Information on Dosage

ADDERALL XR 25 family patents

Family Patents

8. Adderall Xr 30 patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE41148 TAKEDA PHARMS USA Oral pulsed dose drug delivery system
Oct, 2018

(5 years ago)

US6605300 TAKEDA PHARMS USA Oral pulsed dose drug delivery system
Oct, 2018

(5 years ago)

US6322819 TAKEDA PHARMS USA Oral pulsed dose drug delivery system
Oct, 2018

(5 years ago)

USRE42096 TAKEDA PHARMS USA Oral pulsed dose drug delivery system
Oct, 2018

(5 years ago)

US6322819

(Pediatric)

TAKEDA PHARMS USA Oral pulsed dose drug delivery system
Apr, 2019

(5 years ago)

USRE41148

(Pediatric)

TAKEDA PHARMS USA Oral pulsed dose drug delivery system
Apr, 2019

(5 years ago)

USRE42096

(Pediatric)

TAKEDA PHARMS USA Oral pulsed dose drug delivery system
Apr, 2019

(5 years ago)

US6605300

(Pediatric)

TAKEDA PHARMS USA Oral pulsed dose drug delivery system
Apr, 2019

(5 years ago)




How can I launch a generic of ADDERALL XR 30 before it's drug patent expiration?
More Information on Dosage

ADDERALL XR 30 family patents

Family Patents

9. Adderall Xr 5 patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6605300 TAKEDA PHARMS USA Oral pulsed dose drug delivery system
Oct, 2018

(5 years ago)

USRE42096 TAKEDA PHARMS USA Oral pulsed dose drug delivery system
Oct, 2018

(5 years ago)

USRE41148 TAKEDA PHARMS USA Oral pulsed dose drug delivery system
Oct, 2018

(5 years ago)

US6322819 TAKEDA PHARMS USA Oral pulsed dose drug delivery system
Oct, 2018

(5 years ago)

US6322819

(Pediatric)

TAKEDA PHARMS USA Oral pulsed dose drug delivery system
Apr, 2019

(5 years ago)

USRE42096

(Pediatric)

TAKEDA PHARMS USA Oral pulsed dose drug delivery system
Apr, 2019

(5 years ago)

USRE41148

(Pediatric)

TAKEDA PHARMS USA Oral pulsed dose drug delivery system
Apr, 2019

(5 years ago)

US6605300

(Pediatric)

TAKEDA PHARMS USA Oral pulsed dose drug delivery system
Apr, 2019

(5 years ago)




How can I launch a generic of ADDERALL XR 5 before it's drug patent expiration?
More Information on Dosage

ADDERALL XR 5 family patents

Family Patents

10. Alunbrig patent expiration

ALUNBRIG's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9012462 TAKEDA PHARMS USA Phosphorous derivatives as kinase inhibitors
Apr, 2031

(6 years from now)

US10385078 TAKEDA PHARMS USA Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-YL) piperidin-1-YL]phenyl}pyrimidine-2,4-diamine
Nov, 2035

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9273077 TAKEDA PHARMS USA Phosphorus derivatives as kinase inhibitors
May, 2029

(4 years from now)

US9611283 TAKEDA PHARMS USA Methods for inhibiting cell proliferation in ALK-driven cancers
Apr, 2034

(9 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 28, 2022
New Indication(I-847) May 22, 2023
Orphan Drug Exclusivity(ODE-142) Apr 28, 2024
Orphan Drug Exclusivity(ODE) Apr 28, 2024
Orphan Drug Exclusivity(ODE-300) May 22, 2027

Drugs and Companies using BRIGATINIB ingredient

NCE-1 date: 28 April, 2021

Market Authorisation Date: 28 April, 2017

Treatment: Treatment of anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc)

Dosage: TABLET

More Information on Dosage

ALUNBRIG family patents

Family Patents

11. Carbatrol patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5912013 TAKEDA PHARMS USA Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
Jun, 2016

(8 years ago)




Drugs and Companies using CARBAMAZEPINE ingredient

Market Authorisation Date: 30 September, 1997

Treatment: Neurological and other disorders (treatment of epilepsy, bid oral dosing)

Dosage: CAPSULE, EXTENDED RELEASE

How can I launch a generic of CARBATROL before it's drug patent expiration?
More Information on Dosage

CARBATROL family patents

Family Patents

12. Colcrys patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8097655 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and macrolide antibiotics
Oct, 2028

(4 years from now)

US7964648 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and a second active agent
Oct, 2028

(4 years from now)

US7964647 TAKEDA PHARMS USA Colchicine compositions and methods
Oct, 2028

(4 years from now)

US7981938 TAKEDA PHARMS USA Colchicine compositions and methods
Oct, 2028

(4 years from now)

US8093296 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and macrolide antibiotics
Oct, 2028

(4 years from now)

US8093298 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and macrolide antibiotics
Oct, 2028

(4 years from now)

US8415395 TAKEDA PHARMS USA Colchicine compositions and methods
Oct, 2028

(4 years from now)

US8093297 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and a second active agent
Oct, 2028

(4 years from now)

US8415396 TAKEDA PHARMS USA Colchine compositions and methods
Oct, 2028

(4 years from now)

US7619004 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and macrolide antibiotics
Dec, 2028

(4 years from now)

US7935731 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and macrolide antibiotics
Dec, 2028

(4 years from now)

US7601758 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and macrolide antibiotics in the treatment of gout flares
Feb, 2029

(4 years from now)

US7820681 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and a second active agent
Feb, 2029

(4 years from now)

US7906519 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and a second active agent
Feb, 2029

(4 years from now)

US8440722 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and a second active agent
Feb, 2029

(4 years from now)

US8440721 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and a second active agent
Feb, 2029

(4 years from now)

US7915269 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and a second active agent
Feb, 2029

(4 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-603) Jul 30, 2012
Orphan Drug Exclusivity(ODE) Jul 29, 2016

Drugs and Companies using COLCHICINE ingredient

Market Authorisation Date: 29 July, 2009

Treatment: Method of using colchicine for the prophylaxis of gout flares; For the treatment and prophylaxis of gout flares & the treatment of familial mediterranean fever; Method of treating gout flares; A metho...

Dosage: TABLET

How can I launch a generic of COLCRYS before it's drug patent expiration?
More Information on Dosage

COLCRYS family patents

Family Patents

13. Dexilant patent expiration

DEXILANT's oppositions filed in EPO
Can you believe DEXILANT received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9145389 TAKEDA PHARMS USA Benzimidazole compound crystal
Jun, 2020

(4 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6939971 TAKEDA PHARMS USA Benzimidazole compound crystal
Jun, 2020

(4 years ago)

US6664276 TAKEDA PHARMS USA Benzimidazole compound crystal
Jun, 2020

(4 years ago)

US6462058 TAKEDA PHARMS USA Benzimidazole compound crystal
Jun, 2020

(4 years ago)

US7285668 TAKEDA PHARMS USA Process for the crystallization of (R)- or (S)-lansoprazole
Jun, 2020

(4 years ago)

US6462058

(Pediatric)

TAKEDA PHARMS USA Benzimidazole compound crystal
Dec, 2020

(3 years ago)

US6939971

(Pediatric)

TAKEDA PHARMS USA Benzimidazole compound crystal
Dec, 2020

(3 years ago)

US6664276

(Pediatric)

TAKEDA PHARMS USA Benzimidazole compound crystal
Dec, 2020

(3 years ago)

US7285668

(Pediatric)

TAKEDA PHARMS USA Process for the crystallization of (R)- or (S)-lansoprazole
Dec, 2020

(3 years ago)

US8784885 TAKEDA PHARMS USA Controlled release preparation
Oct, 2023

(8 months ago)

US8722084 TAKEDA PHARMS USA Controlled release preparation
Oct, 2023

(8 months ago)

US8784885

(Pediatric)

TAKEDA PHARMS USA Controlled release preparation
Apr, 2024

(2 months ago)

US8722084

(Pediatric)

TAKEDA PHARMS USA Controlled release preparation
Apr, 2024

(2 months ago)

US9238029 TAKEDA PHARMS USA Multiple PPI dosage form
Jan, 2026

(1 year, 6 months from now)

US8461187 TAKEDA PHARMS USA Multiple PPI dosage form
Jan, 2026

(1 year, 6 months from now)

US9011926 TAKEDA PHARMS USA Method for producing granules
Feb, 2026

(1 year, 7 months from now)

US8461187

(Pediatric)

TAKEDA PHARMS USA Multiple PPI dosage form
Jul, 2026

(2 years from now)

US7790755 TAKEDA PHARMS USA Controlled release preparation
Aug, 2026

(2 years from now)

US8105626 TAKEDA PHARMS USA Granules containing acid-unstable chemical in large amount
Sep, 2026

(2 years from now)

US7790755

(Pediatric)

TAKEDA PHARMS USA Controlled release preparation
Feb, 2027

(2 years from now)

US8105626

(Pediatric)

TAKEDA PHARMS USA Granules containing acid-unstable chemical in large amount
Mar, 2027

(2 years from now)

US8871273 TAKEDA PHARMS USA Method for producing granules
Jan, 2028

(3 years from now)

US8173158 TAKEDA PHARMS USA Methods of treating gastrointestinal disorders independent of the intake of food
Mar, 2030

(5 years from now)

US8173158

(Pediatric)

TAKEDA PHARMS USA Methods of treating gastrointestinal disorders independent of the intake of food
Sep, 2030

(6 years from now)

US9233103 TAKEDA PHARMS USA Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy
Mar, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jan 30, 2012
Pediatric Exclusivity(PED) Jul 30, 2012
New Patient Population(NPP) Jul 08, 2019

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Market Authorisation Date: 30 January, 2009

Treatment: Treatment of heartburn associated with non-erosive gastroesophageal reflux disease (gerd) for 4 weeks; Healing of all grades of erosive esophagitis (ee) for up to 8 weeks; Maintain healing of erosive ...

Dosage: CAPSULE, DELAYED RELEASE

How can I launch a generic of DEXILANT before it's drug patent expiration?
More Information on Dosage

DEXILANT family patents

Family Patents

14. Dexilant Solutab patent expiration

DEXILANT SOLUTAB's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6462058 TAKEDA PHARMS USA Benzimidazole compound crystal
Jun, 2020

(4 years ago)

US9145389 TAKEDA PHARMS USA Benzimidazole compound crystal
Jun, 2020

(4 years ago)

US7285668 TAKEDA PHARMS USA Process for the crystallization of (R)- or (S)-lansoprazole
Jun, 2020

(4 years ago)

US6664276 TAKEDA PHARMS USA Benzimidazole compound crystal
Jan, 2023

(1 year, 5 months ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7399485 TAKEDA PHARMS USA Rapidly Disintegrable solid preparation
May, 2018

(6 years ago)

US7399485

(Pediatric)

TAKEDA PHARMS USA Rapidly Disintegrable solid preparation
Nov, 2018

(5 years ago)

US6238994 TAKEDA PHARMS USA Method of creating a rough electrode (high surface area) from Ti and TiN and resulting article
May, 2019

(5 years ago)

US6328994 TAKEDA PHARMS USA Orally disintegrable tablets
May, 2019

(5 years ago)

US7875292 TAKEDA PHARMS USA Orally disintegrable tablets
May, 2019

(5 years ago)

US7431942 TAKEDA PHARMS USA Orally disintegrable tablets
May, 2019

(5 years ago)

US7431942

(Pediatric)

TAKEDA PHARMS USA Orally disintegrable tablets
Nov, 2019

(4 years ago)

US7875292

(Pediatric)

TAKEDA PHARMS USA Orally disintegrable tablets
Nov, 2019

(4 years ago)

US6328994

(Pediatric)

TAKEDA PHARMS USA Orally disintegrable tablets
Nov, 2019

(4 years ago)

US6238994

(Pediatric)

TAKEDA PHARMS USA Method of creating a rough electrode (high surface area) from Ti and TiN and resulting article
Nov, 2019

(4 years ago)

US6939971 TAKEDA PHARMS USA Benzimidazole compound crystal
Jun, 2020

(4 years ago)

US7285668

(Pediatric)

TAKEDA PHARMS USA Process for the crystallization of (R)- or (S)-lansoprazole
Dec, 2020

(3 years ago)

US6462058

(Pediatric)

TAKEDA PHARMS USA Benzimidazole compound crystal
Dec, 2020

(3 years ago)

US6939971

(Pediatric)

TAKEDA PHARMS USA Benzimidazole compound crystal
Dec, 2020

(3 years ago)

US6664276

(Pediatric)

TAKEDA PHARMS USA Benzimidazole compound crystal
Jul, 2023

(11 months ago)

US8784885 TAKEDA PHARMS USA Controlled release preparation
Oct, 2023

(8 months ago)

US8784885

(Pediatric)

TAKEDA PHARMS USA Controlled release preparation
Apr, 2024

(2 months ago)

US9238029 TAKEDA PHARMS USA Multiple PPI dosage form
Jan, 2026

(1 year, 6 months from now)

US8461187 TAKEDA PHARMS USA Multiple PPI dosage form
Jan, 2026

(1 year, 6 months from now)

US9011926 TAKEDA PHARMS USA Method for producing granules
Feb, 2026

(1 year, 7 months from now)

US8461187

(Pediatric)

TAKEDA PHARMS USA Multiple PPI dosage form
Jul, 2026

(2 years from now)

US8871273 TAKEDA PHARMS USA Method for producing granules
Jan, 2028

(3 years from now)

US8871273

(Pediatric)

TAKEDA PHARMS USA Method for producing granules
Jul, 2028

(3 years from now)

US9241910 TAKEDA PHARMS USA Orally-disintegrating solid preparation
Mar, 2029

(4 years from now)




Drugs and Companies using DEXLANSOPRAZOLE ingredient

Market Authorisation Date: 26 January, 2016

Treatment: Treatment of heartburn associated with non-erosive gastroesophageal reflux disease (gerd) for 4 weeks; Maintain healing of erosive esophagitis (ee) for up to 6 months

Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE

More Information on Dosage

DEXILANT SOLUTAB family patents

Family Patents

15. Duetact patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6150383 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(8 years ago)

US6211205 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(8 years ago)

US7538125 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(8 years ago)

US6329404 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(8 years ago)

US6303640 TAKEDA PHARMS USA Pharmaceutical composition
Aug, 2016

(7 years ago)

US7700128 TAKEDA PHARMS USA Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester
Jan, 2027

(2 years from now)

US8071130 TAKEDA PHARMS USA Solid preparation
Jun, 2028

(3 years from now)




Drugs and Companies using GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE ingredient

Market Authorisation Date: 28 July, 2006

Treatment: As an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes

Dosage: TABLET

How can I launch a generic of DUETACT before it's drug patent expiration?
More Information on Dosage

DUETACT family patents

Family Patents

16. Eohilia patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11197822 TAKEDA PHARMS USA Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
Nov, 2026

(2 years from now)

US8679545 TAKEDA PHARMS USA Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
Nov, 2026

(2 years from now)

US11413296 TAKEDA PHARMS USA Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
Nov, 2026

(2 years from now)

US8497258 TAKEDA PHARMS USA Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
Nov, 2026

(2 years from now)

US9119863 TAKEDA PHARMS USA Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
Nov, 2026

(2 years from now)

US8975243 TAKEDA PHARMS USA Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
Nov, 2026

(2 years from now)

US11357859 TAKEDA PHARMS USA Compositions for the treatment of gastrointestinal inflammation
Nov, 2028

(4 years from now)

US10293052 TAKEDA PHARMS USA Compositions for the treatment of gastrointestinal inflammation
Nov, 2028

(4 years from now)

US9050368 TAKEDA PHARMS USA Corticosteroid compositions
Aug, 2029

(5 years from now)

US8324192 TAKEDA PHARMS USA Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
Aug, 2029

(5 years from now)

US11260064 TAKEDA PHARMS USA Stable corticosteroid compositions
Jan, 2039

(14 years from now)

US11564934 TAKEDA PHARMS USA Stable corticosteroid compositions
Jan, 2039

(14 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Feb 09, 2027
Orphan Drug Exclusivity(ODE-466) Feb 09, 2031

Drugs and Companies using BUDESONIDE ingredient

Market Authorisation Date: 09 February, 2024

Treatment: Treatment of eosinophilic esophagitis

Dosage: SUSPENSION

More Information on Dosage

EOHILIA family patents

Family Patents

17. Exkivity patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10227342 TAKEDA PHARMS USA Heteroaryl compounds for kinase inhibition
May, 2035

(10 years from now)

US9796712 TAKEDA PHARMS USA Heteroaryl compounds for kinase inhibition
May, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 15, 2026
Orphan Drug Exclusivity(ODE-374) Sep 15, 2028

Drugs and Companies using MOBOCERTINIB SUCCINATE ingredient

NCE-1 date: 15 September, 2025

Market Authorisation Date: 15 September, 2021

Treatment: Treatment of patients with non-small cell lung cancer (nsclc) with epidermal growth factor receptor (egfr) exon 20 exon insertion mutations whose disease has progressed on or after platinum-based chem...

Dosage: CAPSULE

More Information on Dosage

EXKIVITY family patents

Family Patents

18. Firazyr patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5648333 TAKEDA PHARMS USA Peptides having bradykinin antagonist action
Jul, 2014

(10 years ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 25, 2016
Orphan Drug Exclusivity(ODE-14) Aug 25, 2018
Orphan Drug Exclusivity(ODE) Aug 25, 2018

Drugs and Companies using ICATIBANT ACETATE ingredient

NCE-1 date: 26 August, 2015

Market Authorisation Date: 25 August, 2011

Treatment: Treatment of pathological state by antagonizing bradykinin receptor including treatment of acute attacks of hereditary angioedema (hae)

Dosage: INJECTABLE

How can I launch a generic of FIRAZYR before it's drug patent expiration?
More Information on Dosage

FIRAZYR family patents

Family Patents

19. Fosrenol patent expiration

FOSRENOL's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5968976 TAKEDA PHARMS USA Pharmaceutical composition containing selected lanthanum carbonate hydrates
Oct, 2018

(5 years ago)

US7465465 TAKEDA PHARMS USA Pharmaceutical formulation comprising lanthanum compounds
Aug, 2024

(a month from now)

US7381428 TAKEDA PHARMS USA Stabilized lanthanum carbonate compositions
Aug, 2024

(a month from now)

US8980327 TAKEDA PHARMS USA Capsule and powder formulations containing lanthanum compounds
Dec, 2030

(6 years from now)

US9023397 TAKEDA PHARMS USA Capsule and powder formulations containing lanthanum compounds
Dec, 2030

(6 years from now)




Drugs and Companies using LANTHANUM CARBONATE ingredient

Market Authorisation Date: 23 November, 2005

Treatment: Reduction of serum phosphate; Reduction of serum phosphate in patients with end stage renal disease

Dosage: POWDER; TABLET, CHEWABLE

How can I launch a generic of FOSRENOL before it's drug patent expiration?
More Information on Dosage

FOSRENOL family patents

Family Patents

20. Fruzaqla patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7829574 TAKEDA PHARMS USA Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
May, 2028

(3 years from now)

US10519142 TAKEDA PHARMS USA Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide
Sep, 2035

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8212033 TAKEDA PHARMS USA Use of substituted quinazoline compounds in treating angiogenesis-related diseases
May, 2028

(3 years from now)

US11046674 TAKEDA PHARMS USA Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide
Sep, 2035

(11 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 30, 2028

Drugs and Companies using FRUQUINTINIB ingredient

NCE-1 date: 01 December, 2027

Market Authorisation Date: 08 November, 2023

Treatment: Treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, anti-vegf therapy, and, if ras wild-ty...

Dosage: CAPSULE

More Information on Dosage

FRUZAQLA family patents

Family Patents

21. Gattex Kit patent expiration

GATTEX KIT IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5789379 TAKEDA PHARMS USA Glucagon-like peptide-2 analogs
Apr, 2015

(9 years ago)

US5789379

(Pediatric)

TAKEDA PHARMS USA Glucagon-like peptide-2 analogs
Oct, 2020

(3 years ago)

US7056886 TAKEDA PHARMS USA GLP-2 formulations
Sep, 2022

(1 year, 9 months ago)

US7056886

(Pediatric)

TAKEDA PHARMS USA GLP-2 formulations
Mar, 2023

(1 year, 3 months ago)

US9592274 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 3 months from now)

US9968655 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 3 months from now)

US9981016 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 3 months from now)

US9572867 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 3 months from now)

US9968658 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 3 months from now)

US9968656 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 3 months from now)

US9974835 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 3 months from now)

US9987335 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 3 months from now)

US9974837 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 3 months from now)

US9555079 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 3 months from now)

US9539310 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 3 months from now)

US9981014 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 3 months from now)

US7847061 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 3 months from now)

US9987334 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 3 months from now)

US9545434 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 3 months from now)

US9060992 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 3 months from now)

US9545435 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 3 months from now)

US9592273 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 3 months from now)

US9993528 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 3 months from now)

US9572867

(Pediatric)

TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(1 year, 9 months from now)

US9968655

(Pediatric)

TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(1 year, 9 months from now)

US9968656

(Pediatric)

TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(1 year, 9 months from now)

US7847061

(Pediatric)

TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(1 year, 9 months from now)

US9974837

(Pediatric)

TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(1 year, 9 months from now)

US9974835

(Pediatric)

TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(1 year, 9 months from now)

US9968658

(Pediatric)

TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(1 year, 9 months from now)

US9981016

(Pediatric)

TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(1 year, 9 months from now)

US9060992

(Pediatric)

TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(1 year, 9 months from now)

US9555079

(Pediatric)

TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(1 year, 9 months from now)

US9545434

(Pediatric)

TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(1 year, 9 months from now)

US9539310

(Pediatric)

TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(1 year, 9 months from now)

US9993528

(Pediatric)

TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(1 year, 9 months from now)

US9987335

(Pediatric)

TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(1 year, 9 months from now)

US9592273

(Pediatric)

TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(1 year, 9 months from now)

US9592274

(Pediatric)

TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(1 year, 9 months from now)

US9981014

(Pediatric)

TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(1 year, 9 months from now)

US9545435

(Pediatric)

TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(1 year, 9 months from now)

US9987334

(Pediatric)

TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(1 year, 9 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 21, 2017
Orphan Drug Exclusivity(ODE-37) Dec 21, 2019
Orphan Drug Exclusivity(ODE) Dec 21, 2019
Pediatric Exclusivity(PED) Jun 21, 2020
Orphan Drug Exclusivity(ODE-240) May 16, 2026

Drugs and Companies using TEDUGLUTIDE ingredient

NCE-1 date: 22 June, 2019

Market Authorisation Date: 21 December, 2012

Treatment: Treatment of adult patients with short bowel syndrome who are dependent on parenteral support

Dosage: POWDER

More Information on Dosage

GATTEX KIT family patents

Family Patents

22. Iclusig patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8114874 TAKEDA PHARMS USA Substituted acetylenic imidazo[1,2-B]pyridazine compounds as kinase inhibitors
Jan, 2027

(2 years from now)

US11192897 TAKEDA PHARMS USA Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt
Dec, 2033

(9 years from now)

US11384086 TAKEDA PHARMS USA Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1- yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt
Dec, 2033

(9 years from now)

US9493470 TAKEDA PHARMS USA Crystalline forms of 3-(imidazo[1,2-B] pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt
Dec, 2033

(9 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9029533 TAKEDA PHARMS USA Substituted acetylenic imidazo[1,2-A]pyridazines as kinase inhibitors
Dec, 2026

(2 years from now)

US11192895 TAKEDA PHARMS USA Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt
Dec, 2033

(9 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 14, 2017
Orphan Drug Exclusivity(ODE-35) Dec 14, 2019
Orphan Drug Exclusivity(ODE) Dec 14, 2019
New Indication(I-849) Dec 18, 2023
New Indication(I-934) Mar 19, 2027
Orphan Drug Exclusivity(ODE-472) Mar 19, 2031

Drugs and Companies using PONATINIB HYDROCHLORIDE ingredient

NCE-1 date: 14 December, 2016

Market Authorisation Date: 18 December, 2020

Treatment: A method of treating chronic myelogenous leukemia; A method for treating chronic myeloid leukemia; A method for treating philadelphia chromosome positive acute lymphoblastic leukemia

Dosage: TABLET

How can I launch a generic of ICLUSIG before it's drug patent expiration?
More Information on Dosage

ICLUSIG family patents

Family Patents

23. Intuniv patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5854290 TAKEDA PHARMS USA Use of guanfacine in the treatment of behavioral disorders
Sep, 2015

(8 years ago)

US5854290

(Pediatric)

TAKEDA PHARMS USA Use of guanfacine in the treatment of behavioral disorders
Mar, 2016

(8 years ago)

US6287599 TAKEDA PHARMS USA Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
Dec, 2020

(3 years ago)

US6287599

(Pediatric)

TAKEDA PHARMS USA Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
Jun, 2021

(3 years ago)

US6811794 TAKEDA PHARMS USA Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
Jul, 2022

(2 years ago)

US6811794

(Pediatric)

TAKEDA PHARMS USA Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
Jan, 2023

(1 year, 6 months ago)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Sep 02, 2012
New Indication(I-635) Feb 25, 2014
New Dosing Schedule(D-145) Nov 19, 2017
M(M-154) Mar 18, 2018
Pediatric Exclusivity(PED) May 19, 2018

Drugs and Companies using GUANFACINE HYDROCHLORIDE ingredient

Market Authorisation Date: 02 September, 2009

Treatment: Treatment of attention-deficit hyperactivity disorder

Dosage: TABLET, EXTENDED RELEASE

How can I launch a generic of INTUNIV before it's drug patent expiration?
More Information on Dosage

INTUNIV family patents

Family Patents

24. Kazano patent expiration

Can you believe KAZANO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8288539 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Jun, 2025

(11 months from now)

US7807689 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Jun, 2028

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6172090 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(8 years ago)

US6150383 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(8 years ago)

US5965584 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(8 years ago)

US6329404 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(8 years ago)

US6166042 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(8 years ago)

US6166043 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(8 years ago)

US6150384 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(8 years ago)

US6211205 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(8 years ago)

US6303640 TAKEDA PHARMS USA Pharmaceutical composition
Aug, 2016

(7 years ago)

US6303661 TAKEDA PHARMS USA Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals
Apr, 2017

(7 years ago)

US7078381 TAKEDA PHARMS USA Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US6890898 TAKEDA PHARMS USA Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US7459428 TAKEDA PHARMS USA Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US8173663 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Mar, 2025

(7 months from now)

US8900638 TAKEDA PHARMS USA Solid preparation comprising alogliptin and metformin hydrochloride
May, 2029

(4 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Jan 25, 2016
New Chemical Entity Exclusivity(NCE) Jan 25, 2018
M(M-177) Apr 05, 2019
M(M-300) Jul 27, 2026

Drugs and Companies using ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE ingredient

NCE-1 date: 25 January, 2017

Market Authorisation Date: 25 January, 2013

Treatment: Methods of reducing the side effects of active components administered to a diabetic patient comprising administering an insulin sensitivity enhancer such as pioglitazone in combination with a biguani...

Dosage: TABLET

How can I launch a generic of KAZANO before it's drug patent expiration?
More Information on Dosage

KAZANO family patents

Family Patents

25. Lialda patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6773720 TAKEDA PHARMS USA Mesalazine controlled release oral pharmaceutical compositions
Jun, 2020

(4 years ago)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-640) Jul 14, 2014
New Patient Population(NPP) Jun 26, 2023

Drugs and Companies using MESALAMINE ingredient

Market Authorisation Date: 16 January, 2007

Treatment: NA

Dosage: TABLET, DELAYED RELEASE

How can I launch a generic of LIALDA before it's drug patent expiration?
More Information on Dosage

LIALDA family patents

Family Patents

26. Livtencity patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11684632 TAKEDA PHARMS USA Maribavir isomers, compositions, methods of making and methods of using
Jan, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 23, 2026
Orphan Drug Exclusivity(ODE-388) Nov 23, 2028

Drugs and Companies using MARIBAVIR ingredient

NCE-1 date: 23 November, 2025

Market Authorisation Date: 23 November, 2021

Treatment: Treatment of patients with post-transplant cytomegalovirus (cmv) infection/disease refractory to treatment with ganciclovir, valganciclovir, cidofovir, or foscarnet, where the patient is a stem cell, ...

Dosage: TABLET

More Information on Dosage

LIVTENCITY family patents

Family Patents

27. Mydayis patent expiration

MYDAYIS IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE41148 TAKEDA PHARMS USA Oral pulsed dose drug delivery system
Oct, 2018

(5 years ago)

USRE42096 TAKEDA PHARMS USA Oral pulsed dose drug delivery system
Oct, 2018

(5 years ago)

US6913768 TAKEDA PHARMS USA Sustained release delivery of amphetamine salts
May, 2023

(1 year, 1 month ago)

US9173857 TAKEDA PHARMS USA Controlled dose drug delivery system
May, 2026

(1 year, 9 months from now)

US8846100 TAKEDA PHARMS USA Controlled dose drug delivery system
Aug, 2029

(5 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jun 20, 2020
M(M-248) Sep 13, 2022
Pediatric Exclusivity(PED) Mar 13, 2023

Drugs and Companies using AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE ingredient

Market Authorisation Date: 20 June, 2017

Treatment: Treatment of attention deficit hyperactivity disorder

Dosage: CAPSULE, EXTENDED RELEASE

How can I launch a generic of MYDAYIS before it's drug patent expiration?
More Information on Dosage

MYDAYIS family patents

Family Patents

28. Nesina patent expiration

Can you believe NESINA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8288539 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Mar, 2025

(7 months from now)

US7807689 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Jun, 2028

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6329404 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(8 years ago)

US6211205 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(8 years ago)

US6150383 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(8 years ago)

US6303640 TAKEDA PHARMS USA Pharmaceutical composition
Aug, 2016

(7 years ago)

US6303661 TAKEDA PHARMS USA Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals
Apr, 2017

(7 years ago)

US6890898 TAKEDA PHARMS USA Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US7078381 TAKEDA PHARMS USA Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US7459428 TAKEDA PHARMS USA Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US8173663 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Dec, 2025

(1 year, 4 months from now)

US8697125 TAKEDA PHARMS USA Tablet preparation without causing a tableting trouble
Jun, 2029

(4 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 25, 2018
M(M-177) Apr 05, 2019
M(M-300) Jul 27, 2026

Drugs and Companies using ALOGLIPTIN BENZOATE ingredient

NCE-1 date: 25 January, 2017

Market Authorisation Date: 25 January, 2013

Treatment: Methods of treating diabetes comprising administering an insulin sensitivity enhancer such as pioglitazone in combination with an insulin secretion enhancer; Methods of reducing the amount of active ...

Dosage: TABLET

How can I launch a generic of NESINA before it's drug patent expiration?
More Information on Dosage

NESINA family patents

Family Patents

29. Ninlaro patent expiration

NINLARO's oppositions filed in EPO
Can you believe NINLARO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8546608 TAKEDA PHARMS USA Proteasome inhibitors and methods of using the same
Aug, 2024

(28 days from now)

US8003819 TAKEDA PHARMS USA Proteasome inhibitors
Aug, 2027

(3 years from now)

US7687662 TAKEDA PHARMS USA Proteasome inhibitors
Aug, 2027

(3 years from now)

US8530694 TAKEDA PHARMS USA Proteasome inhibitors
Aug, 2027

(3 years from now)

US8859504 TAKEDA PHARMS USA Boronate ester compounds and pharmaceutical compositions thereof
Jun, 2029

(4 years from now)

US7442830 TAKEDA PHARMS USA Proteasome inhibitors
Nov, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9233115 TAKEDA PHARMS USA Proteasome inhibitors and methods of using the same
Aug, 2024

(28 days from now)

US8871745 TAKEDA PHARMS USA Proteasome inhibitors
Aug, 2027

(3 years from now)

US9175017 TAKEDA PHARMS USA Boronate ester compounds and pharmaceutical compositions thereof
Jun, 2029

(4 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 20, 2020
Orphan Drug Exclusivity(ODE) Nov 20, 2022
Orphan Drug Exclusivity(ODE-103) Nov 20, 2022

Drugs and Companies using IXAZOMIB CITRATE ingredient

NCE-1 date: 21 November, 2019

Market Authorisation Date: 20 November, 2015

Treatment: Use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy

Dosage: CAPSULE

How can I launch a generic of NINLARO before it's drug patent expiration?
More Information on Dosage

NINLARO family patents

Family Patents

30. Omontys patent expiration

Can you believe OMONTYS received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7084245 TAKEDA PHARMS USA Peptides that bind to the erythropoietin receptor
May, 2024

(2 months ago)

US7414105 TAKEDA PHARMS USA Peptides that bind to the erythropoietin receptor
May, 2024

(2 months ago)

US7919118 TAKEDA PHARMS USA Spacer moiety for poly (ethylene glycol) modified peptide based compounds
May, 2024

(2 months ago)

US7528104 TAKEDA PHARMS USA Peptides that bind to the erythropoietin receptor
May, 2024

(2 months ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7919461 TAKEDA PHARMS USA Erythropoietin receptor peptide formulations and uses
Jun, 2026

(1 year, 10 months from now)

US7550433 TAKEDA PHARMS USA Erythropoietin receptor peptide formulations and uses
Jun, 2026

(1 year, 10 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 27, 2017

Drugs and Companies using PEGINESATIDE ACETATE ingredient

NCE-1 date: 27 March, 2016

Market Authorisation Date: 27 March, 2012

Treatment: Treatment of anemia due to chronic kidney disease

Dosage: SOLUTION

More Information on Dosage

OMONTYS family patents

Family Patents

31. Omontys Preservative Free patent expiration

Can you believe OMONTYS PRESERVATIVE FREE received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7919118 TAKEDA PHARMS USA Spacer moiety for poly (ethylene glycol) modified peptide based compounds
May, 2024

(2 months ago)

US7414105 TAKEDA PHARMS USA Peptides that bind to the erythropoietin receptor
May, 2024

(2 months ago)

US7084245 TAKEDA PHARMS USA Peptides that bind to the erythropoietin receptor
May, 2024

(2 months ago)

US7528104 TAKEDA PHARMS USA Peptides that bind to the erythropoietin receptor
May, 2024

(2 months ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7550433 TAKEDA PHARMS USA Erythropoietin receptor peptide formulations and uses
Jun, 2026

(1 year, 10 months from now)

US7919461 TAKEDA PHARMS USA Erythropoietin receptor peptide formulations and uses
Jun, 2026

(1 year, 10 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 27, 2017

Drugs and Companies using PEGINESATIDE ACETATE ingredient

NCE-1 date: 27 March, 2016

Market Authorisation Date: 27 March, 2012

Treatment: Treatment of anemia due to chronic kidney disease

Dosage: SOLUTION

More Information on Dosage

OMONTYS PRESERVATIVE FREE family patents

Family Patents

32. Oseni patent expiration

Can you believe OSENI received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8288539 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Mar, 2025

(7 months from now)

US7807689 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Jun, 2028

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6150383 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(8 years ago)

US6211205 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(8 years ago)

US6150384 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(8 years ago)

US6172090 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(8 years ago)

US6329404 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(8 years ago)

US6166043 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(8 years ago)

US5965584 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(8 years ago)

US6271243 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(8 years ago)

US6166042 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(8 years ago)

US6303640 TAKEDA PHARMS USA Pharmaceutical composition
Aug, 2016

(7 years ago)

US6303661 TAKEDA PHARMS USA Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals
Apr, 2017

(7 years ago)

US6890898 TAKEDA PHARMS USA Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US7078381 TAKEDA PHARMS USA Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US7459428 TAKEDA PHARMS USA Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US8173663 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Mar, 2025

(7 months from now)

US8637079 TAKEDA PHARMS USA Solid preparation comprising alogliptin and pioglitazone
Jun, 2029

(4 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Jan 25, 2016
New Chemical Entity Exclusivity(NCE) Jan 25, 2018
M(M-177) Apr 05, 2019

Drugs and Companies using ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE ingredient

NCE-1 date: 25 January, 2017

Market Authorisation Date: 25 January, 2013

Treatment: Methods of treating lipid metabolism and glycometabolism disorders comprising administering an insulin sensitivity enhancer such as pioglitazone in combination with an insulin secretion enhancer; Meth...

Dosage: TABLET

More Information on Dosage

OSENI family patents

Family Patents

33. Prevacid patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5464632 TAKEDA PHARMS USA Rapidly disintegratable multiparticular tablet
Nov, 2012

(11 years ago)

US5464632

(Pediatric)

TAKEDA PHARMS USA Rapidly disintegratable multiparticular tablet
May, 2013

(11 years ago)

US7399485 TAKEDA PHARMS USA Rapidly Disintegrable solid preparation
May, 2018

(6 years ago)

US7399485

(Pediatric)

TAKEDA PHARMS USA Rapidly Disintegrable solid preparation
Nov, 2018

(5 years ago)

US9901546 TAKEDA PHARMS USA Orally disintegrable tablets
May, 2019

(5 years ago)

US7431942 TAKEDA PHARMS USA Orally disintegrable tablets
May, 2019

(5 years ago)

US7875292 TAKEDA PHARMS USA Orally disintegrable tablets
May, 2019

(5 years ago)

US6328994 TAKEDA PHARMS USA Orally disintegrable tablets
May, 2019

(5 years ago)

US6328994

(Pediatric)

TAKEDA PHARMS USA Orally disintegrable tablets
Nov, 2019

(4 years ago)

US7431942

(Pediatric)

TAKEDA PHARMS USA Orally disintegrable tablets
Nov, 2019

(4 years ago)

US7875292

(Pediatric)

TAKEDA PHARMS USA Orally disintegrable tablets
Nov, 2019

(4 years ago)

US9901546

(Pediatric)

TAKEDA PHARMS USA Orally disintegrable tablets
Nov, 2019

(4 years ago)




Drug Exclusivity Drug Exclusivity Expiration
M(M-85) Oct 28, 2011
Pediatric Exclusivity(PED) Apr 28, 2012

Drugs and Companies using LANSOPRAZOLE ingredient

Market Authorisation Date: 30 August, 2002

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE

How can I launch a generic of PREVACID before it's drug patent expiration?
More Information on Dosage

PREVACID family patents

Family Patents

34. Rozerem patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6034239 TAKEDA PHARMS USA Tricyclic compounds, their production and use
Jul, 2019

(4 years ago)

US10098866 TAKEDA PHARMS USA Pharmaceutical preparation containing copolyvidone
Nov, 2021

(2 years ago)




Drug Exclusivity Drug Exclusivity Expiration
M(M-82) Oct 20, 2011

Drugs and Companies using RAMELTEON ingredient

Market Authorisation Date: 22 July, 2005

Treatment: Method of treating insomnia characterized by difficulty with sleep onset; Method of treating a biological rhythm disorder, such as insomnia

Dosage: TABLET

How can I launch a generic of ROZEREM before it's drug patent expiration?
More Information on Dosage

ROZEREM family patents

Family Patents

35. Trintellix patent expiration

TRINTELLIX's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7144884 TAKEDA PHARMS USA Phenyl-piperazine derivatives as serotonin reuptake inhibitors
Jun, 2026

(1 year, 11 months from now)

US8722684 TAKEDA PHARMS USA 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
Jun, 2031

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8476279 TAKEDA PHARMS USA Phenyl-piperazine derivatives as serotonin reuptake inhibitors
Oct, 2022

(1 year, 9 months ago)

US7144884

(Pediatric)

TAKEDA PHARMS USA Phenyl-piperazine derivatives as serotonin reuptake inhibitors
Dec, 2026

(2 years from now)

US9125908 TAKEDA PHARMS USA 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
Jun, 2027

(2 years from now)

US9227946 TAKEDA PHARMS USA 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment
Jun, 2027

(2 years from now)

US9125909 TAKEDA PHARMS USA 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
Jun, 2027

(2 years from now)

US9125910 TAKEDA PHARMS USA 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
Jun, 2027

(2 years from now)

US9861630 TAKEDA PHARMS USA 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
Jun, 2027

(2 years from now)

US8969355 TAKEDA PHARMS USA 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment
Jun, 2027

(2 years from now)

US11458134 TAKEDA PHARMS USA 1-[2-(2,4-dimeihylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
Jun, 2027

(2 years from now)

US9125908

(Pediatric)

TAKEDA PHARMS USA 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
Dec, 2027

(3 years from now)

US11458134

(Pediatric)

TAKEDA PHARMS USA 1-[2-(2,4-dimeihylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
Dec, 2027

(3 years from now)

US9227946

(Pediatric)

TAKEDA PHARMS USA 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment
Dec, 2027

(3 years from now)

US9125910

(Pediatric)

TAKEDA PHARMS USA 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
Dec, 2027

(3 years from now)

US9125909

(Pediatric)

TAKEDA PHARMS USA 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
Dec, 2027

(3 years from now)

US8969355

(Pediatric)

TAKEDA PHARMS USA 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment
Dec, 2027

(3 years from now)

US9861630

(Pediatric)

TAKEDA PHARMS USA 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
Dec, 2027

(3 years from now)

US8722684

(Pediatric)

TAKEDA PHARMS USA 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
Dec, 2031

(7 years from now)

US9278096 TAKEDA PHARMS USA Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity
Mar, 2032

(7 years from now)

US9278096

(Pediatric)

TAKEDA PHARMS USA Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity
Sep, 2032

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 30, 2018
M(M-227) May 02, 2021
M(M-234) Oct 19, 2021
M(M-267) Nov 13, 2023
M(M-187) Jan 22, 2024
M(M-232) Aug 23, 2026
Pediatric Exclusivity(PED) Feb 23, 2027

Drugs and Companies using VORTIOXETINE HYDROBROMIDE ingredient

NCE-1 date: 23 February, 2026

Market Authorisation Date: 30 September, 2013

Treatment: Method of treating an affective disorder such as depression; Use in the treatment of major depressive disorder to improve processing speed, an aspect of cognitive function; Method of treating depressi...

Dosage: TABLET

How can I launch a generic of TRINTELLIX before it's drug patent expiration?
More Information on Dosage

TRINTELLIX family patents

Family Patents

36. Uloric patent expiration

ULORIC's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5614520 TAKEDA PHARMS USA 2-arylthiazole derivatives and pharmaceutical composition thereof
Mar, 2019

(5 years ago)

US6225474 TAKEDA PHARMS USA Polymorphs of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and method of producing the same
Jun, 2019

(5 years ago)

US7361676 TAKEDA PHARMS USA Solid preparation containing single crystal form
Mar, 2024

(4 months ago)

US8372872 TAKEDA PHARMS USA Methods for concomitant treatment of theophylline and febuxostat
Sep, 2031

(7 years from now)

US9107912 TAKEDA PHARMS USA Methods for concomitant treatment of theophylline and febuxostat
Sep, 2031

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 13, 2014
M(M-205) Aug 15, 2020

Drugs and Companies using FEBUXOSTAT ingredient

NCE-1 date: 13 February, 2013

Market Authorisation Date: 13 February, 2009

Treatment: Chronic management of hyperuricemia in patients with gout. not recommended for the treatment of asymptomatic hyperuricemia; Use of febuxostat for the management of hyperuricemia in patients suffering ...

Dosage: TABLET

How can I launch a generic of ULORIC before it's drug patent expiration?
More Information on Dosage

ULORIC family patents

Family Patents

37. Velcade patent expiration

VELCADE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6083903 TAKEDA PHARMS USA Boronic ester and acid compounds, synthesis and uses
Oct, 2014

(9 years ago)

US6747150 TAKEDA PHARMS USA Boronic ester and acid compounds, synthesis and uses
Oct, 2014

(9 years ago)

US7119080 TAKEDA PHARMS USA Boronic ester and acid compounds, synthesis and uses
Oct, 2014

(9 years ago)

US6297217 TAKEDA PHARMS USA Boronic ester and acid compounds, synthesis and uses
Oct, 2014

(9 years ago)

US6617317 TAKEDA PHARMS USA Boronic ester and acid compositions
Oct, 2014

(9 years ago)

US5780454 TAKEDA PHARMS USA Boronic ester and acid compounds
May, 2017

(7 years ago)

US5780454

(Pediatric)

TAKEDA PHARMS USA Boronic ester and acid compounds
Nov, 2017

(6 years ago)

US6713446 TAKEDA PHARMS USA Formulation of boronic acid compounds
Jan, 2022

(2 years ago)

US6958319 TAKEDA PHARMS USA Formulation of boronic acid compounds
Jan, 2022

(2 years ago)

US6958319

(Pediatric)

TAKEDA PHARMS USA Formulation of boronic acid compounds
Jul, 2022

(1 year, 11 months ago)

US6713446

(Pediatric)

TAKEDA PHARMS USA Formulation of boronic acid compounds
Jul, 2022

(1 year, 11 months ago)




Drug Exclusivity Drug Exclusivity Expiration
NR(NR) Jan 23, 2015
M(M-139) Aug 08, 2017
New Dosing Schedule(D-142) Oct 08, 2017
New Indication(I-695) Oct 08, 2017
New Dosing Schedule(D-141) Oct 08, 2017
M(M-165) Sep 14, 2018
Orphan Drug Exclusivity(ODE-76) Oct 08, 2021
Orphan Drug Exclusivity(ODE) Oct 08, 2021
Pediatric Exclusivity(PED) Apr 08, 2022

Drugs and Companies using BORTEZOMIB ingredient

Market Authorisation Date: 13 May, 2003

Treatment: Treatment of multiple myeloma patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy

Dosage: INJECTABLE

How can I launch a generic of VELCADE before it's drug patent expiration?
More Information on Dosage

VELCADE family patents

Family Patents

38. Vyvanse patent expiration

VYVANSE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7659253 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(1 year, 4 months ago)

US7662787 TAKEDA PHARMS USA Abuse resistant lysine amphetamine compounds
Feb, 2023

(1 year, 4 months ago)

US7655630 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(1 year, 4 months ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7662787 TAKEDA PHARMS USA Abuse resistant lysine amphetamine compounds
Feb, 2023

(1 year, 4 months ago)

US7659253 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(1 year, 4 months ago)

US7659254 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(1 year, 4 months ago)

US7662788 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(1 year, 4 months ago)

US7723305 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(1 year, 4 months ago)

US7655630 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(1 year, 4 months ago)

US7713936 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(1 year, 4 months ago)

US7718619 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(1 year, 4 months ago)

US7671030 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(1 year, 4 months ago)

US7687466 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(1 year, 4 months ago)

US7671031 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(1 year, 4 months ago)

US7674774 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Mar, 2023

(1 year, 3 months ago)

US7678771 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Mar, 2023

(1 year, 3 months ago)

US7678770 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Mar, 2023

(1 year, 3 months ago)

US7687467 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Apr, 2023

(1 year, 3 months ago)

US7105486 TAKEDA PHARMS USA Abuse-resistant amphetamine compounds
Jun, 2023

(1 year, 16 days ago)

US7223735 TAKEDA PHARMS USA Abuse resistant lysine amphetamine compounds
Jun, 2023

(1 year, 16 days ago)

US7700561 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Jun, 2023

(1 year, 16 days ago)

US7655630

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(10 months ago)

US7105486

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine compounds
Aug, 2023

(10 months ago)

US7223735

(Pediatric)

TAKEDA PHARMS USA Abuse resistant lysine amphetamine compounds
Aug, 2023

(10 months ago)

US7723305

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(10 months ago)

US7659253

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(10 months ago)

US7659254

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(10 months ago)

US7662787

(Pediatric)

TAKEDA PHARMS USA Abuse resistant lysine amphetamine compounds
Aug, 2023

(10 months ago)

US7662788

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(10 months ago)

US7671030

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(10 months ago)

US7671031

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(10 months ago)

US7674774

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(10 months ago)

US7713936

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(10 months ago)

US7718619

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(10 months ago)

US7678770

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(10 months ago)

US7678771

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(10 months ago)

US7687466

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(10 months ago)

US7687467

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(10 months ago)

US7700561

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(10 months ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 23, 2012
M(M-82) Apr 05, 2013
New Patient Population(NPP) Nov 10, 2013
New Indication(I-645) Jan 31, 2015
New Indication(I-703) Jan 30, 2018
M(M-188) Oct 14, 2019

Drugs and Companies using LISDEXAMFETAMINE DIMESYLATE ingredient

NCE-1 date: 23 February, 2011

Market Authorisation Date: 30 October, 2014

Treatment: For the treatment of attention deficit hyperactivity disorder (adhd); Treatment of attention deficit hyperactivity disorder (adhd) in adults; Indicated for the treatment of attention-deficit/hyperacti...

Dosage: CAPSULE; TABLET, CHEWABLE

How can I launch a generic of VYVANSE before it's drug patent expiration?
More Information on Dosage

VYVANSE family patents

Family Patents